# Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

> **NCT04707157** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 68 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** LY3556050
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04707157
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-06
- **Primary completion:** 2022-06-13
- **Final completion:** 2022-06-13
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** The trial was slow to enroll, and the sponsor made a business decision to terminate the trial earlier than planned.
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707157, "Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04707157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*